AN2 Therapeutics, Inc. (ANTX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 5.58M USD | Liabilities, Current |
| Cash and equivalents | 44.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 34.07M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.58M | $44.32M | $34.07M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $5.56M | $53.49M | $31.80M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.72M | $19.94M | $38.06M | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $18.00M | $43.92M | (m) | (m) | (m) |
| 2025-06-30 | (m) | (m) | $18.22M | $44.70M | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $19.98M | $47.08M | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | $21.35M | $62.27M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $10.02M | $33.50M | $59.92M | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | $26.77M | $77.77M | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | $24.69M | $89.52M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $14.04M | $15.65M | $91.65M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $14.84M | $32.62M | $91.20M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $11.16M | $40.81M | $54.45M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $8.57M | $26.71M | $61.81M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $7.19M | $27.22M | $68.84M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.43M | $28.80M | $75.58M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $4.15M | $40.62M | $72.77M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.09M | $82.52M | $35.84M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $3.40M | $12.10M | $46.46M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |